Bruker AXS Completes Acquisition of SOCABIM; Expands its Core X-ray Technology Base.

KARLSRUHE, Germany -- Bruker AXS GmbH announced today that it has completed the acquisition of privately-held SOCABIM SAS, a company focused on advanced X-ray analysis software for materials research. This acquisition was originally announced on August 16, 2005, and was expected to close early in 2006.

The acquisition of SOCABIM significantly expands Bruker AXS' core technology base in two of its strategic product and applications areas. It is expected that the addition of the SOCABIM technology and R&D team will further improve the "time-to-market," the analytical power and the user-friendliness of Bruker AXS' X-ray systems for advanced research and process analysis in the nanomaterials, thin film, composite materials, semiconductor and basic materials industries.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on x-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.